HRD-Analyse-Unterscheidung (Myriad myChoice CDx vs FoundationOne CDx)
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BIO-HRD-ASSAY-DISTINCTION |
|---|---|
| Art | Biomarker |
| Aliase | GIS gegen LOH/TAI/LSTUnterscheidung zwischen HRD-TestsHRD-PlattformvergleichРозмежування HRD-аналізів (Myriad myChoice CDx vs FoundationOne CDx) |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-CIVIC SRC-NCCN-COLON-2025 |
Biomarker-Fakten
| Biomarker-Typ | composite_score |
|---|---|
| Messung | VerfahrenZwei FDA-genehmigte Begleitdiagnostikplattformen mit unterschiedlichen Scoring-Systemen: (a) Myriad myChoice CDx — Genomic Instability Score (GIS) kombiniert LOH + TAI + LST als ein einziges zusammengesetztes, Schwellenwert GIS >=42 für HRD-positive; (b) FoundationOne CDx HRD — berichtet LOH-hoch (>=16% genomic LOH) plus BRCA1/2-Status; Aggregate LOH nur, kein TAI oder LST. Beide laufen auf FFPE-Tumor. Einheitencategorical (HRD-positive | HRD-negative); platform-specific cut-points are not interchangeable |
| Verwandte Biomarker | BIO-HRD-STATUS BIO-BRCA1-BRCA2-GERMLINE |
Anmerkungen
Scope: this entity is a methodological / assay-distinction layer on top of BIO-HRD-STATUS. The clinical concept (HRD as a PARPi-response predictor) lives in BIO-HRD-STATUS. This entity records the technical caveats clinicians need when interpreting an HRD report from a specific platform. **Why two assays diverge:** - **Myriad myChoice CDx (companion to olaparib + bevacizumab in PAOLA-1 and niraparib in NOVA / PRIMA):** - Composite Genomic Instability Score (GIS) = LOH + TAI + LST - Threshold: GIS >=42 OR BRCA1/2 mutation -> HRD-positive - Captures three independent genome-scarring footprints (LOH = loss of heterozygosity; TAI = telomeric allelic imbalance; LST = large-scale state transitions) - **FoundationOne CDx HRD (companion to rucaparib in ARIEL3 design; olaparib HRRm-positive subset):** - LOH-high threshold: %LOH >=16% across genome - Does NOT include TAI or LST - More permissive on some BRCA-wt high-grade serous tumors, stricter on others — discordance with myChoice runs ~10-20% in head-to-head series **Clinical implications of the discordance:** - A patient classified HRD-positive on one platform may be classified HRD-negative on the other; this is a known pre-analytic lim...
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.